Jan 15, 2025 7:40 am EST OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Dec 26, 2024 10:01 am EST OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
Nov 15, 2024 9:47 am EST OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 30, 2024 8:51 am EDT Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
Oct 28, 2024 4:44 pm EDT OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors